[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intracranial-artery-stenosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intracranial-artery-stenosis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,81,105,127,156],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100585467","phase-4-pcsk9-inhibitor-with-statin-therapy-for-asymptomatic-intracranial-atherosclerosis-100585467",false,"NCT06902740","PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis","PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis (PISTIAS-2): A Multicenter, Open-label, Blinded-endpoint, Randomized Controlled Trial","PISTIAS-2","Inclusion Criteria:\n\n1. Age ≥18 and ≤80, male or female;\n2. Asymptomatic intracranial artery stenosis (50%-99%) in the internal carotid artery (C6-7 segments), middle cerebral artery (M1 segment), vertebral artery (V4 segment), or basilar artery, confirmed by angiography (MRA, CTA, or DSA);\n3. Atherosclerosis identified as the cause of intracranial artery stenosis by high-resolution magnetic resonance imaging;\n4. No previous ischemic cerebrovascular events (including ischemic stroke or transient ischemic attack).\n5. Baseline low-density lipoprotein cholesterol ≥ 1.8 mmol\u002FL;\n6. Informed consent signed.\n\nExclusion Criteria:\n\n1. Non-atherosclerotic intracranial artery stenosis, including arterial dissection; moya moya disease; systemic vasculitis and primary central nervous system vasculitis; varicella-zoster vasculopathy or other viral vasculopathy; neurosyphilis and other intracranial infections, radiation vasculopathy; fibromuscular dysplasia, sickle cell disease, neurofibromatosis; reversible cerebral vasoconstriction syndrome; postpartum vasculopathy; suspected vasospasm, suspected reperfusion after vessel occlusion.\n2. Upstream tandem extracranial vessel stenosis (≥50%) adjacent to the target intracranial stenotic vessel.\n3. Previous treatment of target intracranial lesion with endovascular intervention or plan to perform endovascular intervention within 6 months, including intracranial stenting, endovascular angioplasty, and thrombectomy.\n4. Any intracranial hemorrhage (parenchymal, subarachnoid, subdural, extradural, intraventricular) within 90 days prior to enrollment.\n5. Presence of intracranial tumors.\n6. Presence of cerebral aneurysms or arteriovenous malformations with indications for interventional therapy.\n7. Major surgery (including open femoral, aortic, or carotid surgery) within previous 30 days or planned in the next 6 months after enrollment.\n8. Presence of any of the following unequivocal cardiac sources of embolism: mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, chronic or paroxysmal atrial fibrillation.\n9. New York Heart Association (NYHA) class III or IV, or known left ventricular ejection fraction \\\u003C 30%.\n10. Severe liver dysfunction or severe kidney dysfunction: AST and\u002For ALT \\> 3 times the ULN; creatinine clearance \\\u003C 0.6 mL\u002Fs and\u002For serum creatinine \\> 265 μmol\u002FL (\\>3.0 mg\u002FdL); CK \\>5 times the ULN at screening.\n11. Active bleeding diathesis or coagulopathy (e.g., active peptic ulcer disease, major systemic hemorrhage within 30 days, active bleeding diathesis, platelets count \\\u003C 125,000 \u002F uL, hematocrit \\\u003C 30%, Hgb \\\u003C 10 g\u002Fdl, international normalized ratio \\>1.5, bleeding time \\> 1 minute beyond normal value upper limit).\n12. Presence of systemic autoimmune diseases: systemic sclerosis, systemic lupus erythematosus, Sjögren's syndrome, Behçet's disease, mixed connective tissue disease, IgG4-related disease.\n13. Dementia or psychiatric problem that hinder their ability to consistently adhere to an outpatient program. Co-morbid conditions that may limit the life expectancy to less than 3 years.\n14. Relative\u002Fabsolute contraindications to magnetic resonance imaging (MRI) (such as presence of internal metallic objects, claustrophobia, contrast agent allergy, severe renal impairment, epilepsy, hypotension, asthma, and other hypersensitivity respiratory diseases).\n15. Uncontrolled hypertension during the screening period, defined as seated systolic blood pressure (SBP) \\> 180 mmHg or diastolic blood pressure (DBP) \\> 110 mmHg.\n16. Prior use of PCSK9 inhibitor before this recruitment.\n17. Known intolerance or allergy to statin.\n18. Pregnancy, lactation, or planning pregnancy.\n19. Currently participating in another study.","ALL","18 Years","80 Years",{"count":21,"type":22},300,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This is a prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial designed to evaluate the efficacy and safety of PCSK9 inhibitor combined with statin therapy compared to statin monotherapy in reversing asymptomatic intracranial atherosclerosis, assessed using high-resolution magnetic resonance imaging of the intracranial vessel walls.",[28,29,30],"Intracranial Atherosclerosis","Intracranial Artery Stenosis","Atherosclerotic Plaque",[28,32,33,34,35,36,37],"intracranial artery stenosis","atherosclerotic plaque","high-resolution magnetic resonance imaging","PCSK9 inhibitor","statin","Recaticimab","RECRUITING","2026-06-10",{"date":41,"type":42},"2026-06-12","ACTUAL",{"date":44,"type":42},"2025-11-07",{"date":46,"type":22},"2028-12-31",{"name":48,"class":49},"Peking Union Medical College Hospital","OTHER",19,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100469791","improving-blood-lipid-management-in-symptomatic-intracranial-atherosclerotic-stenosis-on-clinical-outcome-100469791","NCT05397405","Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome","A Prospective Observational Study on the Effect of Improving Blood Lipid Management on the Clinical Prognosis of Symptomatic Intracranial Atherosclerotic Stenosis（sICASBLM）","sICASBLM","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Symptomatic intracranial atherosclerotic stenosis of moderate to severe, did not receive intravenous thrombolysis, thrombectomy, stent implantation and other intravascular treatment\n3. low density lipoprotein cholesterol \\> 70mg\u002Fdl (1.8mmol\u002FL)\n4. Receive 3T magnetic resonance angiography or multi-mode MR (high resolution is required), angiography can be included, and images for analysis can be obtained.\n5. Lipid-lowering indications of statins\n6. Signed an approved informed consents\n\nExclusion Criteria:\n\n1. Contraindications to statins\n2. There are contraindications to MRI examination or cannot accept MRI examination\n3. Stenosis caused by vasculitis, arterial dissection and moyamoya disease\n4. Patients with active bleeding or obvious bleeding tendency\n5. Severe heart, lung, renal insufficiency, malignant tumor or other malignant diseases, and death is highly likely within 7 days; pregnancy or women who are lactating\n6. Uncontrolled severe diabetes and hypertension\n7. Other conditions inappropriate for inclusion judged by investigators","85 Years",{"count":61,"type":22},180,[63],"NA","sICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C\\>1.8mmol\u002FL) without endovascular therapy.",[29],[67,68,69,70],"symptomatic intracranial atherosclerotic stenosis","stroke","blood lipid management","PCSK9 inhibitors","2026-04-10",{"date":73,"type":42},"2026-04-15",{"date":75,"type":42},"2022-05-23",{"date":77,"type":22},"2026-05-01",{"name":79,"class":49},"Nanjing First Hospital, Nanjing Medical University",2,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":104},"100606059","efficacy-and-safety-of-a-new-balloon-microcatheter-in-the-treatment-of-intracranial-artery-stenosis-100606059","NCT07170618","Efficacy and Safety of a New Balloon Microcatheter in the Treatment of Intracranial Artery Stenosis","A Prospective, Multicenter, Objective Performance Criteria Study to Evaluate the Efficacy and Safety of a Balloon Microcatheter for Clinical Use","Inclusion Criteria:\n\n1. 18 to 80 years of age\n2. Patients with intracranial artery stenosis (Degree of stenosis: ≥70%)\n3. Target vessel reference diameter must be visually estimated to be 1.25 mm to 4.50 mm\n4. Willingness to participate in this clinical trial and signing the consent form for patients or their legally authorised representatives\n\nExclusion Criteria:\n\n1. The proximal end of the target vessel is extremely tortuous, severely angulated, or heavily calcified, making it difficult for the device to reach the target vessel\n2. Pre-existing severe respiratory, hepatic, or renal diseases (e.g., creatinine ≥ 3.0 mg\u002FdL) or coagulation disorders\n3. Disabling stroke with a baseline mRS score ≥ 3 points\n4. Non-atherosclerosis diseases\n5. Patients with stroke caused by branch occlusion\n6. Patients who were participating in other clinical trials who had not yet reached the primary clinical endpoint\n7. Known hypersensitivity to aspirin, heparin, anesthetics and contrast agents\n8. Investigators consider the patient who is not suitable for enrolling in the present trial",{"count":89,"type":22},56,[63],"The primary objective of this trial is to evaluate the safety and efficacy of a new balloon microcatheter in patients with intracranial artery stenosis.",[29],"NOT_YET_RECRUITING","2025-09-04",{"date":96,"type":42},"2025-09-12",{"date":98,"type":22},"2025-09-01",{"date":100,"type":22},"2025-12-30",{"name":102,"class":103},"Sinomed Neurovita Technology Inc.","INDUSTRY",1,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":112,"maxAge":19,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":126,"locationsCount":104},"100599500","gut-microbiota-and-prognostic-outcomes-in-intracranial-arterial-stenosis-patientsgrow-icas-100599500","NCT07085299","Gut Microbiota and Prognostic Outcomes in Intracranial Arterial Stenosis Patients（GROW-ICAS）","Correlation Study Between Gut Microbiota and Prognosis in Patients With Intracranial Arterial Stenosis（GROW-ICAS）","Inclusion Criteria:\n\n1. Age 30-80 years.\n2. Intracranial arterial stenosis confirmed by CTA\u002FMRA\u002FDSA.\n3. Local residency ≥6 consecutive months.\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Tandem extracranial stenosis (≥50%) proximal to the target intracranial stenotic vessel.\n2. Non-atherosclerotic intracranial stenosis.\n3. Extracranial\u002Fintracranial endovascular treatment within 30 days pre-enrollment or planned intervention within 6 months.\n4. Intracranial hemorrhage within 90 days pre-enrollment.\n5. Pre-existing intracranial tumor, cerebral aneurysm, or arteriovenous malformation.\n6. Cardioembolic embolism.\n7. Active bleeding\u002Fhemorrhagic diathesis.\n8. Major surgery within 30 days pre-enrollment or planned within 6 months post-enrollment.\n9. Severe neurological deficits impairing independent living or dementia\u002Fpsychiatric disorders hindering follow-up.\n10. Pregnancy\u002Flactation\u002Fplanned pregnancy.\n11. Chronic inflammatory\u002Fautoimmune diseases.\n12. Uncontrolled hypertension or diabetes.\n13. Severe cardiac\u002Fhepatic\u002Frenal dysfunction, hematologic disorders, malignancy, or life expectancy \\\u003C1 year.\n14. MRI contraindications.\n15. History of depression\u002Fanxiety\u002Fcognitive impairment requiring therapy.\n16. Antibiotic\u002Fprobiotic\u002Fglucocorticoid\u002Fimmunosuppressant use within 1 month pre-enrollment.\n17. Current\u002Fplanned participation in other trials.\n18. Inability to cooperate due to psychiatric\u002Femotional disorders.\n19. Other investigator-deemed ineligibility.","30 Years",{"count":114,"type":22},500,"OBSERVATIONAL","GROW-ICAS (Gut microBiota and prOgnostic Outcomes in IntraCranial Arterial Stenosis) is a prospective observational cohort study that enrolls patients with intracranial arterial stenosis to investigate the correlations between their gut microbiota, metabolomic, and transcriptomic profiles and three key clinical domains: functional outcomes, vascular plaque imaging characteristics, and post-stroke non-motor dysfunctions (including cognitive impairment, depression, anxiety, and fatigue).",[29],[32,119],"Gut Microbiota","2025-07-17",{"date":122,"type":42},"2025-07-25",{"date":124,"type":42},"2025-06-01",{"date":46,"type":22},{"name":79,"class":49},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":142,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100492495","a-registry-study-of-intracranial-atherosclerotic-stenosis-treatment-by-intracranial-drug-eluting-stenting-in-china-100492495","NCT05692882","A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China","To Evaluate the Safety and Efficacy of the NOVA Intracranial Drug-eluting Stent System in \"real World\" Patients with Intracranial Atherosclerotic Stenosis: a Prospective, Multicenter, Post-marketing Registry Clinical Study (NOVA II)","Inclusion Criteria:\n\n1. Males or females between 18 and 80 years of age;\n2. Symptomatic intracranial arteriosclerosis stenosis with reference diameter 2.25-4.00mm;\n3. intracranial artery stenosis ( ≥70%) conformed by digital subtraction angiography (DSA);\n4. Those who voluntarily participate in the study and sign informed consent form.\n\nExclusion Criteria:\n\n1. Those who have surgery within previous 30 days or plan to perform major surgery in the next 90 days (surgery grade 3 and above);\n2. Subjects of acute hemorrhagic stroke within 3 months;\n3. The baseline mRS of disabling stroke is more than 3;\n4. The target vessel is severely calcified and closely related to stenosis;\n5. Non-atherosclerotic diseases (e.g. arterial dissection, Moya Moya disease, vascular inflammatory lesions caused by infection, autoimmune diseases, post-irradiation, postpartum status; developmental or genetic abnormalities such as fibromuscular dysplasia, sickle cell anemia, suspected vasospasm);\n6. It is suspected that the ischemic event is due to embolism or arterial embolism from the extracranial segment (including ipsilateral chest or neck vascular occlusive disease) or potential cardiogenic embolism (e.g. atrial fibrillation, mitral stenosis, patent foramen ovale, left ventricular thrombus, myocardial infarction within 6 weeks, etc.);\n7. Target artery's supplying artery stenosis \\> 50%. For example, patient with middle cerebral artery (MCA) severe stenosis (target artery) and the ipsilateral internal carotid artery (ICA) stenosis \\> 50% should be excluded; patient with basilar artery (BA) severe stenosis (target artery) and the dominant vertical artery (VA) stenosis \\> 50% should be excluded;\n8. There are intracranial tumors, or intracranial arteriovenous malformations;\n9. Those who are allergic to heparin, aspirin, clopidogrel, contrast agents, anesthetics, and stent components;\n10. Pregnant and lactating women\n11. Those who are unable to complete follow-up because of mental illness, cognitive or emotional disorders;\n12. Inapplicable for this study at the investigators' viewpoints.",{"count":135,"type":22},1000,[63],"The primary objective of this trial is to evaluate the long-term safety and efficacy of the NOVA intracranial drug-eluting stent system in \"real world\" patients with intracranial atherosclerotic stenosis.",[139,140,141,29],"Intracranial Arteriosclerosis","Stenosis Artery","Drug-Eluting Stents",[143,144,145],"endovascular therapy","intracranial drug-eluting stent","symptomatic intracranial artery stenosis (sICAS)","2025-03-26",{"date":148,"type":42},"2025-04-01",{"date":150,"type":42},"2023-11-16",{"date":152,"type":22},"2029-12-30",{"name":154,"class":103},"Sino Medical Sciences Technology Inc.",5,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":162,"maxAge":19,"enrollmentInfo":163,"targetDuration":4,"studyType":115,"phases":4,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":104},"100561836","a-prospective-cohort-of-patients-with-cervicalintracranial-arteries-stenosis-in-china-100561836","NCT06595342","A Prospective Cohort of Patients With Cervical\u002FIntracranial Arteries Stenosis in China","Inclusion Criteria:\n\n1. Age ≥ 40 and ≤ 80 years;\n2. Ultrasound or imaging examinations indicating cervical artery stenosis and\u002For intracranial artery stenosis (including mild, moderate, severe stenosis, or occlusion);\n3. Willing to participate and signing the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with stroke occurring within the past year;\n2. Patients with severe systemic diseases, such as respiratory failure, renal failure, gastrointestinal bleeding, coagulation disorders, malignancies, etc.;\n3. Patients with a life expectancy of less than one year or those who are unable to complete the study for other reasons.","40 Years",{"count":164,"type":22},60000,"The aim of this study is to establish a prospective cohort of patients with cervical\u002Fintracranial arteries stenosis in China.",[167,29],"Cervical Artery Stenosis",[167,29],"2024-10-01",{"date":171,"type":42},"2024-10-03",{"date":173,"type":22},"2024-10-30",{"date":175,"type":22},"2030-06-30",{"name":177,"class":49},"The First Hospital of Jilin University"]